当前位置： SCI文献检索 > Cancer Immunology Research期刊下所有文献 > GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

Abstract：

:Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment of advanced malignancies. Although the ability of GITR modulation to induce tumor regression is well-documented in preclinical studies, the underlying mechanisms of action, particularly its effects on CD4(+)foxp3(+) regulatory T cells (Treg), have not been fully elucidated. We have previously demonstrated that GITR ligation in vivo by agonist antibody DTA-1 causes a >50% reduction of intra-tumor Treg with down modulation of Foxp3 expression. Here we show that the loss of Foxp3 is tumor-dependent. Adoptively-transferred Foxp3(+)Treg from tumor-bearing animals lose Foxp3 expression in the host when treated with DTA-1, whereas Treg from naïve mice maintain Foxp3 expression. GITR ligation also alters the expression of various transcription factors and cytokines important for Treg function. Complete Foxp3 loss in intra-tumor Treg correlates with a dramatic decrease in Helios expression and is associated with the upregulation of transcription factors T-Bet and Eomes. Changes in Helios correspond with a reduction in IL-10 and an increase in IFNγ expression in DTA-1-treated Treg. Together, these data show that GITR agonist antibody alters Treg lineage stability inducing an inflammatory effector T cell phenotype. The resultant loss of lineage stability causes Treg to lose their intra-tumor immune suppressive function, making the tumor susceptible to killing by tumor-specific effector CD8(+) T cells.

journal_name

Cancer Immunol Res

journal_title

Cancer immunology research

authors

Schaer DA,Budhu S,Liu C,Bryson C,Malandro N,Cohen A,Zhong H,Yang X,Houghton AN,Merghoub T,Wolchok JD

doi

10.1158/2326-6066.CIR-13-0086

subject

Has Abstract

pub_date

2013-11-01 00:00:00

pages

320-31

issue

5

eissn

2326-6066

issn

2326-6074

journal_volume

1

pub_type

杂志文章

相关文献

Cancer Immunology Research文献大全
  • A Mechanism of Resistance to Antibody-Targeted Immune Attack.

    abstract：:Targeted monoclonal antibody therapy is a promising therapeutic strategy for cancer, and antibody-dependent cell-mediated cytotoxicity (ADCC) represents a crucial mechanism underlying these approaches. The majority of patients have limited responses to monoclonal antibody therapy due to the development of resistance. ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0266

    authors： Aldeghaither DS,Zahavi DJ,Murray JC,Fertig EJ,Graham GT,Zhang YW,O'Connell A,Ma J,Jablonski SA,Weiner LM

    更新日期：2019-02-01 00:00:00

  • STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

    abstract：:The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signal...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0053

    authors： Srivastava RM,Trivedi S,Concha-Benavente F,Hyun-Bae J,Wang L,Seethala RR,Branstetter BF 4th,Ferrone S,Ferris RL

    更新日期：2015-08-01 00:00:00

  • RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells.

    abstract：:Chronic inflammation drives colitis-associated colorectal cancer (CAC) in inflammatory bowel disease (IBD). FoxP3+ regulatory T cells (Treg) coexpressing the Th17-related transcription factor RORγt accumulate in the lamina propria of IBD patients, where they are thought to represent an intermediate stage of developmen...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0698

    authors： Rizzo A,Di Giovangiulio M,Stolfi C,Franzè E,Fehling HJ,Carsetti R,Giorda E,Colantoni A,Ortenzi A,Rugge M,Mescoli C,Monteleone G,Fantini MC

    更新日期：2018-09-01 00:00:00

  • Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

    abstract：:The current standard of care for treatment of metastatic renal cell carcinoma (mRCC) patients is PD-1/PD-L1 inhibitors until progression or toxicity. Here, we characterize the clinical outcomes for 19 mRCC patients who experienced an initial clinical response (any degree of tumor shrinkage), but after immune-related a...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0220

    authors： Martini DJ,Hamieh L,McKay RR,Harshman LC,Brandao R,Norton CK,Steinharter JA,Krajewski KM,Gao X,Schutz FA,McGregor B,Bossé D,Lalani AA,De Velasco G,Michaelson MD,McDermott DF,Choueiri TK

    更新日期：2018-04-01 00:00:00

  • IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities.

    abstract：:The cytokine IL15 is required for survival and activation of natural killer (NK) cells as well as expansion of NK-cell populations. Here, we compare the effects of continuous IL15 infusions on NK-cell subpopulations in cancer patients. Infusions affected the CD56bright NK-cell subpopulation in that the expansion rates...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0279

    authors： Dubois S,Conlon KC,Müller JR,Hsu-Albert J,Beltran N,Bryant BR,Waldmann TA

    更新日期：2017-10-01 00:00:00

  • Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.

    abstract：:Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+), and CD8(+) T cells). Using detailed methods, we investigated the respective ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0089

    authors： Tsuji T,Sabbatini P,Jungbluth AA,Ritter E,Pan L,Ritter G,Ferran L,Spriggs D,Salazar AM,Gnjatic S

    更新日期：2013-11-01 00:00:00

  • Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

    abstract：:Granulocytic-macrophage colony-stimulating factor (GM-CSF) is used as an adjuvant in cancer vaccine trials and has the potential to enhance antitumor efficacy with immunotherapy; however, its immunologic effects are not fully understood. Here, we report results from a phase I study of neoadjuvant GM-CSF in patients wi...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0042

    authors： Wei XX,Chan S,Kwek S,Lewis J,Dao V,Zhang L,Cooperberg MR,Ryan CJ,Lin AM,Friedlander TW,Rini B,Kane C,Simko JP,Carroll PR,Small EJ,Fong L

    更新日期：2016-11-01 00:00:00

  • Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma.

    abstract：:Therapeutic cancer vaccines targeting melanoma-associated antigens are commonly immunogenic but are rarely effective in promoting objective clinical responses. To identify critical molecules for activation of effective antitumor immunity, we have profiled autologous dendritic cell (DC) vaccines used to treat 35 patien...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-20-0274

    authors： Maurer DM,Adamik J,Santos PM,Shi J,Shurin MR,Kirkwood JM,Storkus WJ,Butterfield LH

    更新日期：2020-12-01 00:00:00

  • Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.

    abstract：:Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable successes in fighting B-cell leukemias/lymphomas. Promising response rates are reported in patients treated with B-cell maturation antigen (BCMA) CAR T cells for multiple myeloma. However, responses appear to be nondurable, highlighting the need to ex...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-20-0118

    authors： Globerson Levin A,Rawet Slobodkin M,Waks T,Horn G,Ninio-Many L,Deshet Unger N,Ohayon Y,Suliman S,Cohen Y,Tartakovsky B,Naparstek E,Avivi I,Eshhar Z

    更新日期：2020-12-01 00:00:00

  • Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.

    abstract：:Preventive vaccination against tumor-associated endogenous antigens is considered to be an attractive strategy for the induction of a curative immune response concomitant with a long-lasting immunologic memory. The mucin MUC1 is a promising tumor antigen, as its tumor-associated form differs from the glycoprotein form...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0256

    authors： Stergiou N,Gaidzik N,Heimes AS,Dietzen S,Besenius P,Jäkel J,Brenner W,Schmidt M,Kunz H,Schmitt E

    更新日期：2019-01-01 00:00:00

  • Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

    abstract：:Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,评审

    doi：10.1158/2326-6066.CIR-14-0075

    authors： Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

    更新日期：2014-07-01 00:00:00

  • Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

    abstract：:Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical benefits in treatment of established tumors have remained modest. Several immune evasion mechanisms hinder T-cell entry into tumors and their activity within the tumor. Of note, oncolytic adenoviruses are intrinsically immun...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-14-0220-T

    authors： Tähtinen S,Grönberg-Vähä-Koskela S,Lumen D,Merisalo-Soikkeli M,Siurala M,Airaksinen AJ,Vähä-Koskela M,Hemminki A

    更新日期：2015-08-01 00:00:00

  • Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

    abstract：:Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spont...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0675

    authors： Castiello L,Sestili P,Schiavoni G,Dattilo R,Monque DM,Ciaffoni F,Iezzi M,Lamolinara A,Sistigu A,Moschella F,Pacca AM,Macchia D,Ferrantini M,Zeuner A,Biffoni M,Proietti E,Belardelli F,Aricò E

    更新日期：2018-06-01 00:00:00

  • Transfer of MicroRNA via Macrophage-Derived Extracellular Vesicles Promotes Proneural-to-Mesenchymal Transition in Glioma Stem Cells.

    abstract：:Proneural-to-mesenchymal transition (PMT) is a common process in glioblastoma (GBM) progression that leads to increased radiotherapy resistance. However, the mechanism underlying PMT is poorly understood. Here, we found that tumor-associated macrophages triggered PMT in glioma stem cells (GSC) via small extracellular ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0759

    authors： Zhang Z,Xu J,Chen Z,Wang H,Xue H,Yang C,Guo Q,Qi Y,Guo X,Qian M,Wang S,Qiu W,Gao X,Zhao R,Guo X,Li G

    更新日期：2020-07-01 00:00:00

  • CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance.

    abstract：:Radiotherapy (RT) represents one of the main anticancer approaches for the treatment of solid tumors. Beyond the expected direct effects of RT on tumor cells, evidence supporting the importance of an immune response to RT is growing. The balance between RT-mediated immunogenic and tolerogenic activity is ill-defined a...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0633

    authors： Mondini M,Loyher PL,Hamon P,Gerbé de Thoré M,Laviron M,Berthelot K,Clémenson C,Salomon BL,Combadière C,Deutsch E,Boissonnas A

    更新日期：2019-03-01 00:00:00

  • Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer.

    abstract：:Natural killer T (NKT) cells are glycolipid-reactive lymphocytes that promote cancer control. In previous studies, NKT-cell activation improved survival and antitumor immunity in a postsurgical mouse model of metastatic breast cancer. Herein, we investigated whether NKT-cell activation could be combined with chemother...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0229

    authors： Gebremeskel S,Lobert L,Tanner K,Walker B,Oliphant T,Clarke LE,Dellaire G,Johnston B

    更新日期：2017-12-01 00:00:00

  • Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.

    abstract：:In the context of cancer, naïve T cells are insufficiently primed and become progressively dysfunctional. Boosting antitumor responses by blocking PD-1 or CTLA-4 results in durable clinical responses only in a limited proportion of cancer patients, suggesting that other pathways must be targeted to improve clinical ef...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0103-T

    authors： Bransi A,Salgado OC,Beffinger M,Milo K,Silina K,Yagita H,Becher B,Knuth A,van den Broek M

    更新日期：2015-11-01 00:00:00

  • Direct Detection and Quantification of Neoantigens.

    abstract：:Many immunotherapeutic approaches under development rely on T-cell recognition of cancer-derived peptides bound to human leukocyte antigen molecules on the cell surface. Direct experimental demonstration that such peptides are processed and bound is currently challenging. Here, we describe a method that meets this cha...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0107

    authors： Wang Q,Douglass J,Hwang MS,Hsiue EH,Mog BJ,Zhang M,Papadopoulos N,Kinzler KW,Zhou S,Vogelstein B

    更新日期：2019-11-01 00:00:00

  • Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

    abstract：:Ipilimumab, a novel immune checkpoint inhibitor, is associated with long-term survival in approximately 20% of patients with advanced melanoma and is also being evaluated in the adjuvant setting. With this growing cohort of survivors, long-term health outcomes, chronic toxicities, and functional outcomes among survivo...

    journal_title：Cancer immunology research

    pub_type： 临床试验,杂志文章

    doi：10.1158/2326-6066.CIR-14-0217

    authors： Johnson DB,Friedman DL,Berry E,Decker I,Ye F,Zhao S,Morgans AK,Puzanov I,Sosman JA,Lovly CM

    更新日期：2015-05-01 00:00:00

  • Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.

    abstract：:Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,评审

    doi：10.1158/2326-6066.CIR-15-0194

    authors： Gilboa E,Berezhnoy A,Schrand B

    更新日期：2015-11-01 00:00:00

  • Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.

    abstract：:CD169 (sialoadhesin) is a sialic acid receptor that is specifically expressed on macrophages, including lymph node sinus macrophages. Animal studies suggest that CD169(+) macrophages in lymph nodes have properties in preventing cancers. In order to determine the significance of CD169(+) macrophages in patients with ma...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-14-0180

    authors： Saito Y,Ohnishi K,Miyashita A,Nakahara S,Fujiwara Y,Horlad H,Motoshima T,Fukushima S,Jinnin M,Ihn H,Takeya M,Komohara Y

    更新日期：2015-12-01 00:00:00

  • Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.

    abstract：:Vaccinia virus (VACV) is a double-stranded DNA virus that devotes a large portion of its 200 kbp genome to suppressing and manipulating the immune response of its host. Here, we investigated how targeted removal of immunomodulatory genes from the VACV genome impacted immune cells in the tumor microenvironment with the...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0703

    authors： Umer BA,Noyce RS,Franczak BC,Shenouda MM,Kelly RG,Favis NA,Desaulniers M,Baldwin TA,Hitt MM,Evans DH

    更新日期：2020-05-01 00:00:00

  • Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype.

    abstract：:Macroenvironmental factors, including a patient's physical and social environment, play a role in cancer risk and progression. Our previous studies show that living in an enriched environment (EE) providing complex stimuli confers an anticancer phenotype in mice mediated, in part by a specific neuroendocrine axis, wit...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0297

    authors： Xiao R,Bergin SM,Huang W,Slater AM,Liu X,Judd RT,Lin ED,Widstrom KJ,Scoville SD,Yu J,Caligiuri MA,Cao L

    更新日期：2016-06-01 00:00:00

  • Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.

    abstract：:Recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the premetastatic niche. Here, we compared the growth and metastasis...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-20-0312

    authors： Yang J,Yan C,Vilgelm AE,Chen SC,Ayers GD,Johnson CA,Richmond A

    更新日期：2020-11-11 00:00:00

  • Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

    abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0200-T

    authors： Jhaveri DT,Kim MS,Thompson ED,Huang L,Sharma R,Klein AP,Zheng L,Le DT,Laheru DA,Pandey A,Jaffee EM,Anders RA

    更新日期：2016-03-01 00:00:00

  • NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors.

    abstract：:With the advancement of personalized cancer immunotherapies, new tools are needed to identify tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit clinically relevant tumor progression. Key transgenic mouse models of breast cancer are generated and maintained on the FVB geneti...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0298

    authors： DeVette CI,Andreatta M,Bardet W,Cate SJ,Jurtz VI,Jackson KW,Welm AL,Nielsen M,Hildebrand WH

    更新日期：2018-06-01 00:00:00

  • c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.

    abstract：:Monoclonal antibodies (mAb) can modulate cancer cell signal transduction and recruit antitumor immune effector mechanisms-including antibody-dependent cellular cytotoxicity (ADCC). Although several clinically effective antibodies can promote ADCC, therapeutic resistance is common. We hypothesized that oncogenic signal...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-14-0083

    authors： Murray JC,Aldeghaither D,Wang S,Nasto RE,Jablonski SA,Tang Y,Weiner LM

    更新日期：2014-12-01 00:00:00

  • B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer.

    abstract：:Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8+ T cells and resistance to immunotherapeutic interventions. Cancer-associated mechanisms that elicit CD8+ T-cell exclusion and resistance to immunotherapy are not well-known. Here, using a Kras- and p53-...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0349

    authors： Mirlekar B,Michaud D,Lee SJ,Kren NP,Harris C,Greene K,Goldman EC,Gupta GP,Fields RC,Hawkins WG,DeNardo DG,Rashid NU,Yeh JJ,McRee AJ,Vincent BG,Vignali DAA,Pylayeva-Gupta Y

    更新日期：2020-03-01 00:00:00

  • Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.

    abstract：:Immune checkpoint inhibitors are promising treatments for patients with a variety of malignancies. Toward understanding the determinants of response to immune checkpoint inhibitors, it was previously demonstrated that the presence of somatic mutations is associated with benefit from checkpoint inhibition. A hypothesis...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0019

    authors： Nathanson T,Ahuja A,Rubinsteyn A,Aksoy BA,Hellmann MD,Miao D,Van Allen E,Merghoub T,Wolchok JD,Snyder A,Hammerbacher J

    更新日期：2017-01-01 00:00:00

  • Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.

    abstract：:Tumor-infiltrating lymphocytes (TIL) in colorectal cancer liver metastases (CLM) have been associated with more favorable patient outcomes, but whether MHC class I (MHC-I) expression on cancer cells affects prognosis is uncertain. Immunohistochemistry was performed on a tissue microarray of 158 patients with CLM, who ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0180

    authors： Turcotte S,Katz SC,Shia J,Jarnagin WR,Kingham TP,Allen PJ,Fong Y,D'Angelica MI,DeMatteo RP

    更新日期：2014-06-01 00:00:00